ACADIA Pharmaceuticals Inc. (ACAD) Financials

ACAD Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 749.0 million 317.2 million
2023-09-30 632.5 million 270.4 million
2023-06-30 642.8 million 247.0 million
2023-03-31 655.3 million 281.0 million

ACAD Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 85.4 million 18.0 million
2023-09-30 -59.0 million 18.5 million
2023-06-30 -31.8 million 15.2 million
2023-03-31 -17.9 million 14.7 million

ACAD Net Income

No data available :(

ACAD Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 438.9 million - 57.2 million
2023-09-30 345.9 million - 48.1 million
2023-06-30 375.4 million - 49.8 million
2023-03-31 402.9 million - 51.4 million

ACAD Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 166.5 million
2023-09-30 164.2 million
2023-06-30 165.0 million
2023-03-31 162.3 million

ACAD Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 66.7 million 111.5 million -
2023-09-30 50000 157.0 million 97.9 million -
2023-06-30 40.0 million 58.8 million 96.0 million -
2023-03-31 69.6 million 69.1 million 101.2 million -

ACAD Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 231.0 million 17.9 million
2023-09-30 211.7 million 14.6 million
2023-06-30 165.2 million 7.5 million
2023-03-31 118.5 million 1.7 million

ACAD

Price: $17.05

52 week price:
16.31
33.99

Earnings Per Share: -0.37 USD

P/E Ratio: -27.67

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 1.4 million

Ebitda: -65.6 million

Market Capitalization: 2.9 billion

Links: